Merck gets priority review for Welireg
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...
Visitors can capture their photos with the Red Card at the stand to contribute to a powerful visual Mosaic symbol of ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
RFK Jr. played a lead role in building an case against Merck's HPV vaccine and could profit from the lawsuit alleging fraud, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback